FLRY3 logo

Fleury S.A. Stock Price

BOVESPA:FLRY3 Community·R$8.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

FLRY3 Share Price Performance

R$15.48
0.72 (4.88%)
20.6% undervalued intrinsic discount
R$19.50
Fair Value
R$15.48
0.72 (4.88%)
20.6% undervalued intrinsic discount
R$19.50
Fair Value
Price R$15.48
AnalystHighTarget R$19.50
AnalystConsensusTarget R$15.97
AnalystLowTarget R$12.25

FLRY3 Community Narratives

AnalystHighTarget·
Fair Value R$19.5 19.9% undervalued intrinsic discount

Aging Population And AI Will Redefine Preventive Healthcare

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value R$15.97 2.3% undervalued intrinsic discount

Digital Investments And Demographics Will Transform Diagnostic Medicine

1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AnalystLowTarget·
Fair Value R$12.5 24.9% overvalued intrinsic discount

Rising Inequality In Brazil And Digital Disruption Will Compress Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent FLRY3 News & Updates

Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Sep 24
Fleury (BVMF:FLRY3) Has A Pretty Healthy Balance Sheet

Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking

Jun 19
Investor Optimism Abounds Fleury S.A. (BVMF:FLRY3) But Growth Is Lacking

Fleury's (BVMF:FLRY3) Solid Earnings Are Supported By Other Strong Factors

May 17
Fleury's (BVMF:FLRY3) Solid Earnings Are Supported By Other Strong Factors

Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Apr 15
Does Fleury (BVMF:FLRY3) Have A Healthy Balance Sheet?

Fleury S.A. Key Details

R$7.8b

Revenue

R$5.7b

Cost of Revenue

R$2.1b

Gross Profit

R$1.5b

Other Expenses

R$606.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
1.11
Gross Margin
26.92%
Net Profit Margin
7.73%
Debt/Equity Ratio
75.4%

Fleury S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet, good value and pays a dividend.

1 Risk
2 Rewards

About FLRY3

Founded
1926
Employees
27000
CEO
Jeane Tsutsui
WebsiteView website
ri.fleury.com.br

Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and clinical research in oncology; integrated solutions, research, development of processes and services in genomics; and laboratory analysis services. In addition, it operates a health platform, immunobiological drug infusion center, and ophthalmology service centers. Fleury S.A. was founded in 1926 and is headquartered in São Paulo, Brazil.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Brazilian Market Performance

  • 7 Days: -2.0%
  • 3 Months: 1.0%
  • 1 Year: -0.1%
  • Year to Date: 10.7%
Over the last 7 days, the market has dropped 1.5%, driven by a pullback of 1.5% in the Financials sector. In the last 12 months the market has been flat overall. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›